Tag Archives: Still

#FierceMadness pharma ad contest narrows: Pfizer, Bayer, Novartis, ViiV and Biohaven among the Elite Eight still standing

FierceMadess voters have spoken—and now, just an Elite Eight pharma advertisers are still in the running for the 2021 title.  Pfizer, Bayer, Novartis, Roche, Johnson & Johnson and GlaxoSmithKline’s ViiV Healthcare are among the Big Pharma contenders still playing in the DTC ad campaign contest, while Evofem Biosciences and Biohaven Pharmaceuticals are the smaller upstarts looking for… Read More »

Pfizer’s much-anticipated COVID-19 vaccine data have yet to materialize. Can it still roll out this year?

With a bold prediction that interim data on its COVID-19 shot would be in the public’s hands by October, all eyes have been on Pfizer and CEO Albert Bourla. But with just days to go before November, those data still aren’t available—and Pfizer is holding on to hope that it can still roll out the… Read More »

KLAS: Organizations Still Struggling with Remote Patient Monitoring

Jacob Jeppson, Director of Analysis, Arch Collaborative, KLAS In a time when it seemed we couldn’t have been further apart, what we needed was to come together — intellectually speaking, that is. At the beginning of the pandemic, before everything shut down, we were fortunate enough to be preparing for our committee meetings with Arch… Read More »

I’m an OBGYN, 30 Weeks Pregnant and Still Working During COVID-19

Reproductive health in the age of COVID-19 is a topic we’re extremely interested in covering. We are a platform that is inclusive to all mothers. We want to deliver important mommy news to all families out there. If you’ve been reading any of our coverage, you’ll notice that a certain incredible doctor has been giving us the… Read More »

Minorities and medical research: Who is still excluded?

Katie Kinsella and Ximena Verduzco-Villanueva | Policy | July 6, 2020 In the United States, there is clear evidence that minority populations continue to be underrepresented in clinical research related to new therapies for common and serious long-term medical conditions such as type 2 diabetes (T2D). This is despite these same populations facing a continuing… Read More »